You just read:

New Four- and Five-Year Survival Data for YERVOY® (ipilimumab) in Treatment-Naïve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology)

News provided by

Bristol-Myers Squibb

29 Sep, 2012, 12:00 BST